Washington, D.C. — The Alliance for Biosecurity today announced its strong endorsement of recently introduced bipartisan legislation, H.R. 2707 – Protecting American Families and Servicemembers from Anthrax Act, introduced on April 8, 2025, by Representatives Don Davis (D-NC) and Jen Kiggans (R-VA).
The legislation takes a critical step toward modernizing the United States’ strategy to defend against anthrax threats and serves as a vital framework for broader chemical, biological, radiological, and nuclear (CBRN) preparedness. Other cosponsors of the legislation include Reps. Jack Bergman (R-MI), Brad Finstad (R-MN), Deborah Ross (D-NC), and Pat Harrigan (R-NC), representing a bipartisan collection of national security and public health leaders.
H.R. 2707 reflects a coordinated approach to national biodefense and includes key provisions that are directly aligned with the Alliance’s mission to strengthen U.S. biosecurity, including:
- Developing a comprehensive, long-term national strategy to counter anthrax threats;
- Enhancing coordination between the Department of Defense (DoD) and Department of Health and Human Services (HHS) to improve readiness and rapid response capabilities;
- Advancing stockpiling and research and development efforts to meet current threat-driven requirements for anthrax;
- Strengthening the resilience of supply chains for critical biodefense resources; and
- Increasing transparency and accountability through annual reporting on the Strategic National Stockpile (SNS).
“The Alliance for Biosecurity commends Representatives Davis and Kiggans for their leadership in advancing this urgently-needed Anthrax preparedness legislation,” said Alliance Secretariat and former Congressman, Jack Kingston. “H.R. 2707 is an important step in establishing a modernized and coordinated biodefense strategy that protects servicemembers, their families, and all Americans from biological threats.”
By endorsing H.R. 2707, the Alliance continues to advocate for policies that ensure the development, procurement, and availability of essential, lifesaving medical countermeasures that meet threat-driven requirements. The bill reinforces the importance of strong public-private partnerships and sets a precedent for how the federal government can partner more effectively with industry to advance medical countermeasures across the full CBRN portfolio.
“This bill represents the type of forward-looking, collaborative approach that the Alliance has long supported,” added Kingston. “Its emphasis on coordination, innovation, and accountability can serve as a model for future efforts to strengthen the nation’s biodefense capabilities.”
The Office of the Director of National Intelligence recently reaffirmed its growing and enhanced concern of Chemical and Biological weapons, including Anthrax, from America’s adversaries in its latest Annual Threat Assessment. These elevated concerns, driving the importance of robust countermeasures for these threats, make the passage of H.R. 2707 critical to bolstering national security.
